Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

August 26, 2010

Primary Outcome Measures:

– Feasibility and safety of identification of primary nodal drainage for purpose of radiation therapy targeting [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

– Feasibility of incorporating primary nodal drainage into radiation therapy planning process [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Criteria

Inclusion Criteria:

Either
1. Established primary lung cancer/ cancer metastatic to lung, OR
2. Lesion suspicious for malignancy in lung, according to the following criteria:
  1. Histopathologically confirmed lung cancer or cancer metastatic to lung, OR
  2. Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR
  3. Known metastatic cancer, with metastases to the lung based on imaging
Age > 18 years old
Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix IV)
No prior surgery, chemotherapy, or radiation for the current lung tumor
Both men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

Prior radiotherapy to thorax
Allergy to iodine
Contraindication to receiving radiotherapy, unless undergoing surgery
Women who are pregnant

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

Name

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact